Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.52 |
| ▸ | KDM6B | O15054 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | LIPC | P11150 | 1/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16737192 | 0.90 | PLK1 (0.53) | TAS2R14KDM6BKDM4CGRIK1ALDH1A1 | |
| SCHEMBL3888815 | 0.88 | LIPC (0.63) | TAS2R14KDM6BKDM4CALDH1A1TRPA1 | |
| SCHEMBL15636154 | 0.85 | RXFP1 (0.56) | TAS2R14GRIK1ALDH1A1KDM4EHPGD | |
| SCHEMBL955126 | 0.80 | CFTR (0.42) | ALDH1A1TRPA1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL3888029 | 0.80 | LIPC (0.60) | TAS2R14KDM6BKDM4CALDH1A1KDM4E | |
| SCHEMBL22525059 | 0.80 | TAS2R14 (0.58) | TAS2R14GRIK1ALDH1A1KDM4EHPGD | |
| SCHEMBL17938289 | 0.78 | HCAR3 (0.58) | KDM6BKDM4CALDH1A1KDM4EHPGD | |
| SCHEMBL22852823 | 0.78 | RXFP1 (0.57) | TAS2R14KDM6BKDM4CGRIK1ALDH1A1 | |
| SCHEMBL23141185 | 0.78 | ACLY (0.57) | TAS2R14ALDH1A1HSD17B10ACLYKDM1A | |
| SCHEMBL5325478 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C19PLK1CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238105-B1 | NOVEL COMPOUNDS AS VANILLOID RECEPTOR ANTAGONISTS | AMOREPACIFIC CORP (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2014-01-09 | — | — | US | disclosed |
| US-8557872-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2013-10-15 | — | — | US | disclosed |
| US-20110015230-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-01-20 | — | — | US | disclosed |
| EP-2238105-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009096701-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | TAS2R14 197/4885KDM6B 4807/4885KDM4C 4772/4885 |
| US-20110015230-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | TAS2R14 197/4885KDM6B 4807/4885KDM4C 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.